Ottawa, Calgary

English, Japanese

David Fraser

Patent Agent

David Fraser is a Patent Agent with a wealth of international industry experience in patent monetization and licensing, drafting, and prosecution. David leverages his hands on experience in R&D roles in the drafting and prosecution of patents in a broad range of technologies including electronics, networking, semiconductors, communications, computer architecture, and software. David also has expertise in Fintech, cryptocurrencies, and commercial software.

David’s has extensive experience providing licensing and litigation support to corporate IP groups in Japan (he speaks fluent Japanese), Korea, Taiwan, US, and Europe in the fields of consumer electronics and semiconductors. He also leverages his work in patent acquisitions and licensing in his drafting and prosecution work to obtain the broadest, commercially valuable coverage possible.

David is a Registered Canadian Patent Agent and also has limited recognition to represent Canadians in patent matters before the USPTO.

In his spare time, David is an avid amateur cyclists and volunteers with IAESTE, an international student exchange organization.


  • B.Sc. (Mathematics & Engineering), Queen’s University at Kingston

  • M.A.Sc., Electrical Engineering, University of British Columbia

  • MBA, University of Ottawa

technology areas

  • Digital systems, electronics, and communications networks
  • Semiconductor process and circuits
  • Computer architecture
  • Software and crypto-currencies
  • Financial technology (Fintech)

Professional Involvement

  • Intellectual Property Institute of Canada (IPIC)

Practice Area

cb photo 106 56b90c1f32572

DR. Michael Maskery

Patent Agent

Michael's practice focuses on the patent drafting, prosecution and strategy in a variety of technology fields.MBM read_more_btn


MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

Clarifications to the Data Protection Guidance Document

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for...Read More